Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/10795/000001079519000022/bdx0331201910-q.htm
August 2022
August 2022
May 2022
May 2022
April 2022
April 2022
April 2022
March 2022
March 2022
March 2022
• | As reported, revenues of $4.195 billion decreased 0.6 percent. |
• | On a comparable, currency-neutral basis, revenues increased 3.4 percent. |
• | As reported, diluted earnings per share of $(0.07) increased 63.2 percent. |
• | As adjusted, diluted earnings per share of $2.59 decreased 2.3 percent, and increased 7.2 percent on a currency-neutral basis. |
• | The company reaffirmed its full fiscal year 2019 comparable, currency-neutral revenue guidance, and updated its adjusted diluted earnings per share guidance. |
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/10795/000001079519000022/bdx0331201910-q.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Becton Dickinson Co.
Becton Dickinson Co's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:
Rating
Learn More![]()
Weakness in the global economy and financial markets, which could increase the cost of operating our business, weaken demand for our products and services, negatively impact the prices we can charge for our products and services, or impair our ability to produce our products.
Accounts payable and accrued expenses were lower primarily due to the timing and amount of cash paid related to our product liability matters and income taxes payable.
The effective income tax rate for the six-month period of fiscal year 2019 reflected a favorable impact relating to the timing of certain discrete items, as well as the recognition of $20 million of additional tax expense relating to U.S. tax legislation that was enacted in December 2017, compared with additional tax expense of $275 million that was recognized as a result of this legislation in the prior-year period.
For the three months ended March 31, 2019, worldwide revenues of $4.195 billion decreased 0.6% from the prior-year period which reflected volume growth of over 3%, an unfavorable impact from foreign currency translation of approximately 2.7% and pricing pressures of approximately 0.1%.
Pending and potential future litigation or other proceedings asserting, and/or subpoenas seeking information with respect to, alleged violations of law (including in connection with federal and/or state healthcare programs (such as Medicare or Medicaid) and/or sales and marketing practices (such as investigative subpoenas and the civil investigative demands received by BD and Bard)), antitrust claims, product liability (which may involve lawsuits seeking class action status or seeking to establish multi-district litigation proceedings, including claims relating to our hernia repair implant products, surgical continence products for women and vena cava filter products), claims with respect to environmental matters, and patent infringement, and the availability or collectability of insurance relating to any such claims.
Net other operating expense in...Read more
Volume growth in the second...Read more
The impact of business combinations...Read more
The effect of market fluctuations...Read more
We estimate that the FDA...Read more
The Urology and Critical Care...Read more
This growth in the Peripheral...Read more
Forward-looking statements may be identified...Read more
The increase in selling and...Read more
Operating performance in the current-year...Read more
Revenues in the current-year period...Read more
Security breaches of our information...Read more
BD and its representatives may...Read more
Results on a foreign currency-neutral...Read more
Environmental laws, particularly with respect...Read more
The effective income tax rate...Read more
BD?s worldwide second quarter revenues...Read more
The Warning Letter states that,...Read more
Second quarter international revenue growth...Read more
The Company had no commercial...Read more
Deficit reduction efforts or other...Read more
Second quarter international revenue growth...Read more
Second quarter revenue growth in...Read more
The following table summarizes our...Read more
Revenues for the three months...Read more
A stronger U.S. dollar, compared...Read more
There were no borrowings outstanding...Read more
The foregoing list sets forth...Read more
In addition, pricing pressure exists...Read more
Delays in obtaining necessary approvals...Read more
The impact of this unfavorable...Read more
Our ability to sustain our...Read more
International revenues in the second...Read more
Our investments in capital expenditures...Read more
We may, from time to...Read more
Borrowings outstanding under the term...Read more
For further disclosures regarding restructuring...Read more
The following summarizes second quarter...Read more
This net use of cash...Read more
Competitive factors that could adversely...Read more
All statements that address our...Read more
Revenues in the current-year period...Read more
Our corporate credit ratings with...Read more
Other income (expense), net The...Read more
Risks relating to our acquisition...Read more
The effect of adverse media...Read more
While the economic environment for...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
Becton Dickinson Co provided additional information to their SEC Filing as exhibits
Ticker: BDX
CIK: 10795
Form Type: 10-Q Quarterly Report
Accession Number: 0000010795-19-000022
Submitted to the SEC: Thu May 09 2019 10:51:27 AM EST
Accepted by the SEC: Thu May 09 2019
Period: Sunday, March 31, 2019
Industry: Surgical And Medical Instruments And Apparatus